THANK YOU FOR SUBSCRIBING
With APAC emerging as a hub for cancer-related clinical trials per varied fertility factors, it thrives in oncology treatments.
FREMONT, CA: Clinical trial activity in the Asia-Pacific (APAC) region has likely surged since the previous decade and is anticipated to soar further in future years. Generally, trials conducted in the APAC nations were later-stage studies, which have been highly emphasised in recent times, with an accelerated administration of phase I trials. Similarly, increased growth in the global pharmaceutical sales market contributes to the commercialization of clinical trials in the arena, which has a high potential.
One pivotal factor that is likely transforming APAC as a hotspot for oncology trials is the exponential population growth in the sector, often consisting of treatment-naive patients with eligibility and eagerness to enrol in clinical trials and access novel treatments accordingly. Furthermore, as a result of globalization, the middle-class population has outgrown itself on a massive scale, signs bearing the burden of paying for one's healthcare. It has greatly contributed to increased participation in clinical trials among patients with fewer economic resources.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
APAC is thriving with specialised clinical trial centres, in addition to its active participation as a home to nearly 50.000 principal investigators assisting clinical trials in oncology. Hence, various countries in the nation are making feasible investments to accelerate clinical trial competitiveness via the development of state-of-the-art institutions with innovative equipment, technology, and infrastructure. For instance, the medical centres in Japan and South Korea have created exponential, de-identified patient databases that are often leveraged in evaluating study design, feasibility, and accelerating requirements.
Furthermore, the APAC contract research organisation (CRO) market is expanding rapidly and is expected to reach a value of up to 18 billion USD by 2028. As a result, migrants from overseas are returning to their homelands in the APAC region, along with an emphasis on drug development expertise and global study training. It also favours an intense knowledge of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) for enhanced clinical practice.
In this case, a well-established synergy with skilled personnel reinforced regulations, and oversight has most likely facilitated improved data quality for the conduct of cancer clinical trials. Hence, medical and drug agencies from the US and Europe, like the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are underscoring the importance of data from clinical trials conducted in Asia, thereby inventing a more safe and more accurate treatment for cancer ailments.
Therefore, APAC is considerably thriving as a hotspot for clinical trials in the medical sector, especially in the oncology sector, to cure rare and late-diagnosed cancer ailments effectively.
More in News